A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Clinical trial NCT07085104 · RECRUITING

Trial details

NCT number: NCT07085104
Sponsor: Allogene Therapeutics
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus (With and Without Nephritis)Idiopathic Inflammatory Myopathy Systemic Sclerosis

Start date: 2025-11-13
Primary completion: 2028-02-01
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.